Luceiro Capital Companies

ESEN

Real companies with freely usable public data: official annual reports of European listed companies (ESEF), SEC accounts and ECB exchange rates. No share prices, so there is no market capitalisation, P/E or EV/EBITDA.

Company sheet · analysis as of 21/10/2026

Amgen Inc.

AMGN · Health care · Pharmaceuticals · US · reporting currency USD · LEI 62QBXGPJ34PQ72Z12S66

Share: XNAS · USD · US0311621009 · Price: No data: no share prices up to the analysis date

Reference period: H1 ended 30/06/2026, published on 05/08/2026

← Back to the ranking

Shareholder score without valuation

75

Coverage 83 %

Credit score

17

Coverage 100 %

Alerts

0

Screens passed: 0 of 1

Shareholder view

FactorValueCompared with PercentileWeightContribution
ROE 74.8 % Sector (6 companies) 92 17 % 18.3
ROIC 15.6 % Sector (7 companies) 79 17 % 15.7
Gross margin No data — — 17 % —
LTM gross profit: missing “Gross profit” for FY 31/12/2025, H1 30/06/2026, H1 30/06/2025
EBITDA margin 42.2 % Sector (7 companies) 93 17 % 18.6
Cash conversion 116.4 % Sector (7 companies) 36 17 % 7.1
Revenue growth 9.1 % Sector (7 companies) 79 17 % 15.7
Formulas and inputs

ROE: LTM attributable net income / Attributable equity at period end

LTM attributable net income
8,743.0
Attributable equity
11,688.0

ROIC: LTM EBIT × (1 − notional tax rate) / (Total equity + Financial debt − Cash)

LTM EBIT
11,426.0
Total equity
11,688.0
Financial debt
57,304.0
Cash and equivalents
13,989.0
Notional tax rate
0.2500

Gross margin: LTM gross profit / LTM revenue

EBITDA margin: LTM EBITDA / LTM revenue

LTM EBITDA
16,093.0
LTM revenue
38,095.0

Cash conversion: (LTM operating cash flow − LTM capex) / LTM net income attributable

LTM operating cash flow
12,478.0
LTM capital expenditure (capex)
2,303.0
LTM attributable net income
8,743.0

Revenue growth: LTM revenue / LTM revenue a year earlier − 1

LTM revenue
38,095.0
Prior-year LTM revenue
34,917.0

Amounts in euros

Market capitalisation No data
Enterprise value (EV) No data
LTM revenue 32,666 M EUR
LTM EBITDA 13,800 M EUR
Net debt 38,016 M EUR

Creditor view

FactorValueCompared with PercentileWeightContribution
Net debt/EBITDA 2.7x Sector (7 companies) 21 33 % 7.1
Interest coverage 6.0x Sector (7 companies) 21 33 % 7.1
Debt/equity 4.9x Sector (6 companies) 8 33 % 2.8
Formulas and inputs

Net debt/EBITDA: (Financial debt − Cash) / LTM EBITDA

Financial debt
57,304.0
Cash and equivalents
13,989.0
LTM EBITDA
16,093.0

Interest coverage: LTM EBITDA / LTM interest expense

LTM EBITDA
16,093.0
LTM interest expense
2,668.0

Debt/equity: Financial debt / Total equity

Financial debt
57,304.0
Total equity
11,688.0

Outstanding bonds

The loaded data contain no outstanding bonds of this company.

Alerts

No alerts in this run.

Screens

ScreenResultConditions
Moderate leverage Fails Net debt/EBITDA ≤ 2.5x: value: 2.7x
Interest coverage ≥ 5.0x: value: 6.0x

Annual history (millions of USD)

2023
FY 31/12/2023
2024
FY 31/12/2024
2025
FY 31/12/2025
Revenue28,19033,42436,751
EBITDA11,96812,85014,247
Attributable net income6,7174,0907,711
Free cash flow7,35910,3948,100
Net debt53,66948,12645,475

Each fiscal year is labelled with the calendar year in which most of its months fall.

The scores summarise metrics compared with similar companies, and the alerts point to specific facts. Nothing shown here is a recommendation to buy or sell.